NEW YORK – Seattle-based BrainChild Bio announced Friday that it is advancing its leading drug candidate, a CAR T-cell therapy targeting the immune checkpoint B7-H3 to a registrational trial, to ...

Therapeutics announces that BriaPro is developing novel, high affinity antibodies to B7-H3, a key player in cancer progression, ...

In regenerative science, B7-33's potential to influence fibroblast activity and collagen turnover suggests possible implications for tissue repair and wound healing. Given that fibrosis is often a ...

Briacell Therapeutics Corp.’s subsidiary, Briapro Therapeutics Corp., is developing novel, high affinity antibodies to B7-H3 using molecular modeling techniques. As both an immune checkpoint molecule ...

This clinical plan is based on alignment between BrainChild Bio and FDA at a Type B meeting in late 2024. About Diffuse Intrinsic Pontine Glioma (DIPG) and Application of CAR T-cell Therapies ...

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer ...

PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a ...

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer ...